Pulmonary Fibrosis News and Research

RSS

Rare lung disease cells indicate higher death risk

Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, University of Cincinnati (UC) researchers have discovered.

17 Jan 2008

Smoking belies milder disease but worse prognosis for idiopathic pulmonary fibrosis patients

Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.

16 Jan 2008

Fibrosis in the liver stopped and reversed by researchers

University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed.

28 Dec 2007

Discovery of key mechanism underlying idiopathic pulmonary fibrosis

A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment.

13 Dec 2007

Preventing lung scarring may extend lives of lung cancer patients

Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients – pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

Mortality rates from pulmonary fibrosis will continue to rise

Mortality rates from pulmonary fibrosis (PF) have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado.

2 Aug 2007

First mouse model of lung transplantation

Lung transplants have been performed successfully for more than 20 years in humans but never before in mice – until now.

12 Jul 2007

Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease typically characterized by the slow but progressive onset of shortness of breath or cough.

1 Jun 2007

New form of idiopathic pulmonary fibrosis found

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis.

30 May 2007

New evidence-based guidelines for patients with chronic obstructive pulmonary disease

New evidence-based guidelines from the American College of Chest Physicians (ACCP) and the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) recommend a comprehensive pulmonary rehabilitation program for patients with chronic obstructive pulmonary disease (COPD), citing that pulmonary rehabilitation can help improve a patient's exercise tolerance, dyspnea, and health-related quality of life, as well as decrease hospital stay and health-care utilization.

8 May 2007

Mutations in a gene that helps regulate cell division linked to inherited form of fatal lung disease

Mutations in a gene that helps regulate cell division are responsible for some inherited cases of a fatal lung disease, researchers at UT Southwestern Medical Center have found.

27 Apr 2007

Genetic culprits of idiopathic pulmonary fibrosis

Scientists at Johns Hopkins have identified the genetic culprits that trigger a hereditary form of a fatal lung disease.

30 Mar 2007

Lessons from our patients: development of a warm autopsy program

Thanks in large part to a dying patient's generosity, researchers have for the first time begun to analyze the progression of idiopathic pulmonary fibrosis (IPF), a degenerative illness distinguished by lung inflammation, scarring and diminished breathing capacity that typically leads to death within about five years of diagnosis.

7 Jun 2006

Research could lead to new treatments for idiopathic pulmonary fibrosis

Scientists at the University of Michigan Medical School have identified biochemical signals that attract pathogenic cells to damaged lung tissue - one of the first steps in a chain of events leading to a lethal disease called idiopathic pulmonary fibrosis or IPF.

23 May 2006

Antifibrotic effect of hepatocyte growth factor is impaired in lung fibroblasts isolated from African-Americans

Of the more than 40,000 persons who die each year in the U.S. from pulmonary fibrosis, the mortality rate among African-Americans is twice as high Caucasians.

11 Apr 2006

Fndings could lead to a treatment for idiopathic interstitial pneumonia

An incurable, deadly lung disorder, "idiopathic interstitial pneumonia" (IIP), whose causes were mysterious arises from a combination of a genetic predisposition and damage due to inhaled chemicals, notably from cigarette smoking, Duke University Medical Center researchers have found.

27 Sep 2005

Osteopontin protein found to be more common in patients with lung fibrosis

Idiopathic pulmonary fibrosis (IPF) is a scarring disease without a cure, irreparably damaging the ability of the tissue to transfer oxygen into the bloodstream.

6 Sep 2005

Two proteins for the diagnosis of lung diseases

Lung function pathology takes in some 200 diseases which have much radiological and pathological data in common, and which can greatly shorten the life of the patient, the last resort being a lung transplant.

1 Sep 2005

Female lung transplant recipients more likely to suffer from primary graft dysfunction

Female lung transplant recipients are significantly more likely to suffer from a type of injury to the transplanted lung called primary graft dysfunction than male lung transplant patients, according to a study presented at the American Thoracic Society International Conference.

25 May 2005

Promising results from study of Pirfenidone in idiopathic pulmonary fibrosis (IPF) patients

InterMune today announced that the American Journal of Respiratory and Critical Care Medicine (AJRCCM) published results from a double-blind, randomized, placebo-controlled Phase II trial evaluating pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

2 May 2005